|
Press Releases |
|
|
|
Friday, July 7, 2023 |
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
Friday, June 30, 2023 |
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
Thursday, June 22, 2023 |
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
Monday, June 12, 2023 |
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
Thursday, June 8, 2023 |
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
Friday, June 2, 2023 |
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
Friday, May 26, 2023 |
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
Thursday, May 25, 2023 |
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
Wednesday, May 24, 2023 |
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
Saturday, May 20, 2023 |
|
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
|
|
|
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
|
|
|
8 in 10 Singapore businesses experienced more change in last 4 years than previous two decades: HubSpot Research
Apr 25, 2024 16:00 HKT/SGT
|
|
|
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
|
|
|
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
|
|
|
CITIC Telecom CPC Becomes New VMware Cloud Service Provider Pinnacle Tier Partner in the Broadcom Advantage Partner Program
Apr 25, 2024 13:07 HKT/SGT
|
|
|
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
|
|
|
Elevate Your Sleep Game This World Health Day with LAC
Apr 25, 2024 09:00 HKT/SGT
|
|
|
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 9:00 JST
|
|
|
GA-ASI Selected to Build CCA for AFLCMC
Apr 25, 2024 07:00 HKT/SGT
|
|
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 25, 2024 01:47 HKT/SGT
|
|
|
The South China Sea: A Nuanced Understanding Required
Apr 24, 2024 21:12 HKT/SGT
|
|
|
Kontent.ai Introduces Mission Control and New Brand Identity, Leading a New Era of Content Management
Apr 24, 2024 20:51 HKT/SGT
|
|
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China
Apr 24, 2024 18:59 HKT/SGT
|
|
|
Legacy Credit Emerges as a Substantial Shareholder in VCI Global
Apr 24, 2024 18:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|